By: IPP Bureau
Last updated : November 25, 2025 10:25 am
Jaypirca is making waves in the fight against B-cell malignancies
Eli Lilly and Company has announced that it will unveil pivotal new data on Jaypirca (pirtobrutinib), the first and only approved non-covalent Bruton tyrosine kinase (BTK) inhibitor, at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Dec. 6-9.
Jaypirca is making waves in the fight against B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The presentations will include head-to-head Phase 3 data, late-breaking clinical results, and long-term follow-up from Phase 1/2 studies, highlighting Jaypirca’s potential to transform treatment for patients across multiple disease settings.
“Building on our positive topline results for the BRUIN CLL-313 and CLL-314 studies, we are thrilled to present the full data at ASH,” said Jacob Van Naarden, EVP and President of Lilly Oncology. “Together, these findings underscore Jaypirca’s unique clinical profile and its potential across treatment settings for B-cell malignancies.”
Jaypirca (pirtobrutinib) is a highly selective, reversible BTK inhibitor, 300 times more selective for BTK than most other kinases. It is FDA-approved for: Adults with relapsed or refractory mantle cell lymphoma after at least two prior therapies, including a BTK inhibitor. Adults with CLL or SLL who have received at least two prior therapies, including a BTK and BCL-2 inhibitor.
Taken as a once-daily oral tablet, Jaypirca represents a new frontier in targeted therapy for patients with B-cell malignancies.